Published in Healthcare Mergers, Acquisitions and Ventures Week, February 17th, 2007
The investment, led by Launchpad Venture Group, is intended to support continued development of the Neuroptix QEL platform and diagnostic agents. Neuroptix's technology has demonstrated successful preclinical predictive diagnostic results as the company develops its diagnostic platform - which consists of a laser eye scanning device combined with an eye drop which specifically identifies Alzheimer's-related proteins found in the lens of the eye.
Hambleton Lord, Managing Director of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Healthcare Mergers, Acquisitions and Ventures Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.